Table 1

Characteristics of included trials

Trial name*ArmNAgeMale (%)ECOG 1 (%)Smoke (%)ORR (%)OS
(months)
PFS
(months)
DOR
(months)
HR PFS
(95% CI)
HR OS
(95% CI)
ECOG4599,
2006
TC +bevacizumab41756.050.460.0NR35.012.36.2NR0.66 (0.57 to 0.77)0.79 (0.67 to 0.92)
TC43358.058.460.0NR15.010.34.5NRRefRef
JO19907, 2010TC +bevacizumab12161.063.649.069.060.722.86.96.90.61 (0.42 to 0.89)0.99 (0.65 to 1.50)
TC5960.064.451.068.031.023.45.95.6RefRef
AVAiL, 2010GP +bevacizumab35159.062.459.0NR34.613.46.56.10.85 (0.73 to 1.00)1.03 (0.86 to 1.23)
GP34759.064.359.0NR21.613.16.14.7RefRef
PRONOUNCE, 2015AC18266.057.552.790.123.610.54.4NR1.06 (0.84 to 1.35)1.07 (0.83 to 1.36)
TC +bevacizumab17965.058.153.196.127.411.75.5NRRefRef
ERACLE,
2015
AP6060.070.022.070.040.014.08.1NR0.79 (0.53 to 1.17)0.93 (0.60 to 1.42)
TC +bevacizumab5862.077.621.060.051.714.48.3NRRefRef
BEYOND,
2015
TC +bevacizumab13857.054.375.050.054.024.39.28.00.40 (0.29 to 0.54)0.68 (0.50 to 0.93)
TC13856.055.880.044.026.017.76.55.3RefRef
KEYNOTE-189, 2020AC/P+pembrolizumab41065.062.053.988.348.022.09.011.20.48 (0.40 to 0.58)0.56 (0.45 to 0.70)
AC/P20663.552.960.787.919.410.74.97.8RefRef
KEYNOTE-021, 2020AC+pembrolizumab6062.537.058.075.058.034.524.536.30.54 (0.35 to 0.83)0.71 (0.45 to 1.12)
AC6363.241.054.086.033.021.19.922.8RefRef
IMpower130, 2019Nab-TC +atezolizumab45164.059.058.089.049.218.67.08.40.64 (0.54 to 0.77)0.79 (0.64 to 0.98)
Nab-TC22865.059.060.092.031.913.95.56.1RefRef
IMpower132, 2020AC/p+atezolizumab29264.065.856.8NR47.018.17.610.10.60 (0.49 to 0.72)0.81 (0.64 to 1.03)
AC/P28663.067.159.9NR32.013.65.27.2RefRef
CheckMate 227, 2020AC/P+nivolumab27063.036.061.082.0NR18.88.7NR0.67 (0.55 to 0.82)0.86 (0.69 to 1.08)
AC/P27363.037.069.075.0NR15.55.86.2RefRef
CAMEL,
2019
AC+camrelizumab20559.071.276.6NR60.0NR11.317.60.60 (0.45 to 0.79)0.72 (0.52 to 1.01)
AC20761.072.082.5NR39.120.98.39.9RefRef
RATIONALE 304, 2020AC/P+tislelizumab22360.075.375.865.957.4NR9.78.50.65 (0.46 to 0.90)NR
AC/P11161.071.278.459.536.9NR7.66.0RefNR
ORIENT 11,
2020
AC/P+sintilimab26661.076.771.464.351.9NR8.9NR0.48 (0.36 to 0.64)0.61 (0.40 to 0.93)
AC/P13161.075.674.066.429.8NR5.05.5RefRef
  • *The references for the enrolled trials are listed in online supplemental additional table S1.

  • AC, pemetrexed +carboplatin; AC/P, pemetrexed +carboplatin/cisplatin; AP, pemetrexed +cisplatin; CI, confidence interval; DOR, duration of response; ECOG1, Eastern Cooperative Oncology Group 1; GP, gemcitabine +cisplatin; Nab-TC, nanoparticle albumin-bound paclitaxel +carboplatin; NR, not report; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Ref, reference; TC, paclitaxel +carboplatin.